{"organizations": [], "uuid": "da3884ff2a8c8317ee09f42e1b244fa6ad7f8701", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/3", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/08/globe-newswire-aptose-to-release-fourth-quarter-and-year-end-december-31-2017-financial-results-and-hold-conference-call-on-march-27-2018.html", "country": "US", "domain_rank": 767, "title": "Aptose To Release Fourth Quarter and Year End December 31, 2017 Financial Results and Hold Conference Call on March 27, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.022, "site_type": "news", "published": "2018-03-08T15:00:00.000+02:00", "replies_count": 0, "uuid": "da3884ff2a8c8317ee09f42e1b244fa6ad7f8701"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/08/globe-newswire-aptose-to-release-fourth-quarter-and-year-end-december-31-2017-financial-results-and-hold-conference-call-on-march-27-2018.html", "ord_in_thread": 0, "title": "Aptose To Release Fourth Quarter and Year End December 31, 2017 Financial Results and Hold Conference Call on March 27, 2018", "locations": [], "entities": {"persons": [{"name": "aptose", "sentiment": "none"}], "locations": [{"name": "toronto", "sentiment": "none"}], "organizations": [{"name": "aptose biosciences inc.", "sentiment": "neutral"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SAN DIEGO and TORONTO, March 08, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of patients with life-threatening hematologic cancers, will release its financial results for the quarter and year ended December 31, 2017, on Tuesday, March 27, 2018 after the close of the market. ﻿ ﻿\nConference Call & Webcast:\nTuesday, March 27 th @ 5:00pm Eastern Time Toll-Free: (844) 882-7834 International: (574) 990-9707 Passcode: 8873259 Webcast: https://edge.media-server.com/m6/p/h526hjyv Replays available through April 3 rd , 2018 Toll-Free: (855) 859 2056 Replay Passcode: 8873259 The live conference call can also be accessed through a link on the Investor Relations section of Aptose’s website at ir.aptose.com . Please log onto the webcast at least 10 minutes prior to the start of the call to ensure time for any software downloads that may be required. An archived version of the webcast along with a transcript will be available on the company’s website for 30 days.\nThe press release, the financial statements and the management’s discussion and analysis for the quarter ended and year ended December 31, 2017 will be available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml\nAbout Aptose Biosciences\nAptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com .\nFor further information, please contact:\nAptose Biosciences\nGreg Chow, CFO\n647-479-9828\nEmail: gchow@aptose.com\nSMP Communications\nSusan Pietropaolo\n201-923-2049\nsusan@smpcommunications.com\nLifeSci Advisors\nMichael Wood\nManaging Director\n646-597-6983\nmwood@lifesciadvisors.com\nSource:Aptose Biosciences, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=wYTLCits7yoa74zXL2-Ok8h4gSiUoNugnE88D0Yneva8ewemujwRNP3mMs5M7tTJGhKAi7NSW5ba-ZNv272K9A==", "https://www.globenewswire.com/Tracker?data=Vu66Tuly5apfSGMWE4IMOCfdBhkX5UzX-C6VrVuRYTJ46JTQMVyAlShP5lgSQopYclD2ybCwCH_rhhE7nBMjE7hov1IgZu5yDzcKny2gJo2FdNvvKNUxu1N7V4UF3f5U", "https://www.globenewswire.com/Tracker?data=wYTLCits7yoa74zXL2-Ok7T3LoEKzw6zW3aPW5DNDU05QfhlM5qxczhnv7yOk8fKqgqP0crHrRiAgWgeUg96b3eKQcuiia0jzPEeZTU51Sk=", "https://www.globenewswire.com/Tracker?data=ZT_wy-8r_hXoTO6-pI46Kn_s2H9c9mlOc2kdaFag7gu_LXFKg7kI8GLK7ggdMoTM3pSFR4qjtFrfcHsWa60HNA==", "https://edge.media-server.com/m6/p/h526hjyv", "https://www.globenewswire.com/NewsRoom/AttachmentNg/3f4ab307-5947-4ef1-b5b5-c2c66933728a"], "published": "2018-03-08T15:00:00.000+02:00", "crawled": "2018-03-08T16:36:32.002+02:00", "highlightTitle": ""}